Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA extends review period for Genasense
The FDA said the review period had been extended due to major amendments made by Genta to the drug application after it was submitted. The evaluation period will
The FDA said the review period had been extended due to major amendments made by Genta to the drug application after it was submitted. The evaluation period will
“While medicine has made great strides in treating childhood cancers, some chemotherapies still have unfortunate, and potentially preventable, side effects,” said Penelope Brock, consultant in pediatric oncology, Great
The study will evaluate the safety and tolerability of MB07811. MB07811 uses the company’s proprietary HepDirect prodrug technology to target a beta-subtype-selective thyroid hormone receptor (TRB) agonist to
The phase II clinical trial is designed to determine the efficacy and safety of five different dose and formulation profiles of NG2-73. The primary endpoint will be the
Researchers at the University of Arizona had already shown in an earlier study that turmeric can prevent joint inflammation in rats. In the current study, they expanded their
The primary objective of the study was to measure Strattera’s efficacy in treating the symptoms of ADHD in children and adolescents with ADHD and a comorbid reading disorder.
Multiplexing is a diagnostic testing approach in which multiple targets are screened for in one single test. Multiplexing is typically used in cases where patients present symptoms which
The research assessed the ability of certain peptides (small portions of proteins) identified at Cangene to inhibit surgical wound infections by Staphylococcus aureus bacteria. Often referred to as
Crofelemer is a natural product sustainably harvested from the rain forest. It is extracted from the medicinal plant, Croton lechleri. Trine has worldwide development and commercialization rights to
Maxygen said the agreement would allow the company to use Avimer technology allowing it to develop unique products which have the potential to be important drug targets. Avimer